Non-SSRI Antidepressant Treatments in Pregnancy
Introduction to Non-SSRI Options
- The American College of Obstetricians and Gynecologists recommends bupropion as the primary non-SSRI antidepressant option for treating depression during pregnancy, with atomoxetine serving as an alternative for ADHD-related depression, though both require careful risk-benefit discussion given limited but generally reassuring safety data 1, 2.
First-Line Non-SSRI Option: Bupropion
- Bupropion does not appear to be associated with major congenital malformations or significant adverse obstetrical outcomes, making it a reasonable first-line non-SSRI choice 1, 2.
- The maintenance dose of bupropion is 100-150 mg twice daily (SR formulation) 1, 3.
- The maximum dose of bupropion is 450 mg per day 1, 3.
- No consistent association with major congenital malformations in most studies, but a small absolute increase in two specific cardiovascular malformations reported, including left ventricular outflow tract obstruction heart defects and ventricular septal defects 1, 2.
Alternative Non-SSRI Option: Atomoxetine
- Atomoxetine does not appear to be associated with major congenital malformations, including cardiac malformations, though data are more limited than for bupropion 1, 2, 5.
- The maximum dose of atomoxetine is the lesser of 1.4 mg/kg/day or 100 mg/day 1, 2, 5.
- No association with major congenital malformations or significant adverse obstetrical outcomes in available studies, but possible increased risk for spontaneous abortion 1, 2, 5.
Comparative Context: Why Non-SSRI Over SSRI?
- SSRIs are associated with poor neonatal adaptation syndrome in 13.5-23.6% of exposed infants 6, 7.
- Paroxetine specifically carries increased risk of cardiac malformations and should be avoided in pregnancy 8.
Clinical Decision Algorithm
- If patient has depression without ADHD, consider bupropion as first-line non-SSRI option 3.
- If patient has ADHD with comorbid depression, consider atomoxetine as first-line option 2.